Article
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations.
Future oncology (London, England) - 1 Jan 2024
George Suzanne, Blay Jean-Yves, Chi Ping, Jones Robin L, Serrano César, Somaiah Neeta, Gelderblom Hans, Zalcberg John R, Reichmann William, Sprott Kam, Cox Paulina, Sherman Matthew L, Ruiz-Soto Rodrigo, Heinrich Michael C, Bauer Sebastian
Abstract excerpt
Somatic KIT activating mutations drive most gastrointestinal stromal tumors (GISTs). Disease progression eventually develops with first-line imatinib, commonly due to KIT secondary mutations, and different kinase inhibitors have various levels of treatment efficacy dependent on specific acquired resistance mutations. Ripretinib is a broad-spectrum switch-control KIT/PDGFRA tyrosine kinase inhibitor for patients...
Topics
Join the communities discussing this publication.